Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

Celltrion launches phase 3 trial of COVID-19 mAb

Investigational monoclonal antibody will be tested as a preventative treatment

- PMLiVE

Adapting to a pandemic: small changes can make a big difference

By Peter Impey

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Shionogi’s novel antibiotic trial data published in The Lancet

Data from APEKS-NP and CREDIBLE-CR studies published

- PMLiVE

Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout

Patients treated in intensive care met survival threshold in open-label study

- PMLiVE

Mallinckrodt files for bankruptcy protection in the US

Bankruptcy filing will reduce debts related to legal liabilities

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

- PMLiVE

Bombarded with information – the challenge of crowded digital channels

Chris Ross explores the pursuit of communications excellence in a world of noise

- PMLiVE

NORD Rare Diseases Breakthrough Summit

Gavin Jones, Director of Rare Disease, provides his thoughts on last week’s NORD Breakthrough Summit and a collective need to reduce inequalities in rare disease

OPEN Health

- PMLiVE

Lucid Group are keeping wellness front of mind

It's important to make sure that people are supported and encouraged to practice self-care throughout the year. This is why Lucid Group has been reminding its teams of the LucidBeing...

Lucid Group Communications Limited

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links